Daiichi Sankyo Co., Ltd. – Sponsored ADR (OTCMKTS:DSNKY) Short Interest Down 82.0% in December

Daiichi Sankyo Co., Ltd. – Sponsored ADR (OTCMKTS:DSNKY) was the target of a significant decline in short interest in the month of December. As of December 15th, there was short interest totaling 326 shares, a decline of 82.0% from the November 30th total of 1,809 shares. Approximately 0.0% of the shares of the company are short sold. Based on an average daily volume of 624,935 shares, the short-interest ratio is currently 0.0 days. Based on an average daily volume of 624,935 shares, the short-interest ratio is currently 0.0 days. Approximately 0.0% of the shares of the company are short sold.

Analyst Ratings Changes

Separately, Zacks Research cut Daiichi Sankyo from a “hold” rating to a “strong sell” rating in a research report on Wednesday, November 19th. One equities research analyst has rated the stock with a Strong Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Daiichi Sankyo has an average rating of “Moderate Buy”.

Daiichi Sankyo Price Performance

OTCMKTS DSNKY traded up $0.07 during trading on Thursday, reaching $21.42. 126,159 shares of the company traded hands, compared to its average volume of 292,699. Daiichi Sankyo has a 1-year low of $20.51 and a 1-year high of $29.68. The company has a market cap of $40.58 billion and a price-to-earnings ratio of 20.21. The stock’s 50 day moving average price is $23.44 and its two-hundred day moving average price is $23.91. The company has a debt-to-equity ratio of 0.06, a quick ratio of 1.60 and a current ratio of 2.31.

About Daiichi Sankyo

Daiichi Sankyo Co, Ltd. is a global, research-driven pharmaceutical company headquartered in Tokyo, Japan. The company was formed through the merger of Daiichi Pharmaceutical and Sankyo in 2005 and focuses on the discovery, development, manufacturing and commercialization of prescription medicines. Its therapeutic priorities include oncology and cardiovascular disease, and it pursues a mix of small molecules, biologics and antibody‑drug conjugates in its development programs.

Daiichi Sankyo is known for building a development portfolio through both internal research and collaborative partnerships.